Ono Pharmaceutical Co Ltd 2025 Integrated Report
The report describes Ono's FY2024 value-creation story, centered on the acquisition of Deciphera and the acceleration of its evolution into a Global Specialty Pharma. It explains the reorganization of 18 materialities into nine and expands discussion of human, intellectual and social relationship capital. Environmental highlights include a 70.3% Scope 1 + 2 reduction from FY2017 and 93.2% renewable electricity utilization, while the report also details human-rights, supply-chain and diversity initiatives.
Company: Ono Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2025
Type: Integrated Report
Pages: 97
Back to company
Ono Pharmaceutical Co Ltd
Corporate Report
The report describes Ono's FY2024 value-creation story, centered on the acquisition of Deciphera and the acceleration of its evolution into a Global Specialty Pharma. It explains the reorganization of 18 materialities into nine and expands discussion of human, intellectual and social relationship capital. Environmental highlights include a 70.3% Scope 1 + 2 reduction from FY2017 and 93.2% renewable electricity utilization, while the report also details human-rights, supply-chain and diversity initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees